Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

Blood Cells, Molecules, and Diseases

Volumn 47, Issue 3, 2011, Pages 166-175

  Maggio, Aurelio ^a   Filosa, Aldo ^b   Vitrano, Angela ^a   Aloj, Giuseppina ^b   Kattamis, Antonis ^c   Ceci, Adriana ^d   Fucharoen, Suthat ^e   Cianciulli, Paolo ^f   Grady, Robert W ^g   Prossomariti, Luciano ^h   Porter, John B ⁱ   Iacono, Angela ^j   Cappellini, Maria Domenica ^k   Bonifazi, Fedele ^d,l   Cassarà, Filippo ^a   Harmatz, Paul ^m   Wood, John ⁿ   Gluud, Christian ^o  

^a UOC Ematologia II con Talassemia   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Department of Biostatistics   (Italy)

^e MAHIDOL UNIVERSITY   (Thailand)

^f AO S Eugenio   (Italy)

^g WEILL CORNELL MEDICAL CENTER   (United States)

^h Centro Regionale per la Cura delle Microcitemie   (Italy)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j Foundation Leonardo Giambrone   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l IRIDIA srl   (Italy)

^m CHILDREN S HOSPITAL OAKLAND   (United States)

ⁿ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^o Rigshospitalet   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON; PLACEBO;

ARTICLE; BOLUS INJECTION; CHELATION THERAPY; CLINICAL EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GENETIC HETEROGENEITY; HEART EJECTION FRACTION; HUMAN; IRON CHELATION; IRON URINE LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THALASSEMIA MAJOR; URINARY EXCRETION;

BENZOIC ACIDS; BETA-THALASSEMIA; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MEDLINE; MYOCARDIUM; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIDEROPHORES; TREATMENT OUTCOME; TRIAZOLES; VENTRICULAR FUNCTION;

EID: 80053385222     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.07.002     Document Type: Article

References (50)

1. Weatherall D. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010, 115:4331-4336.
2. Modell B., Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull. World Health Organ. 2008, 86:480-487.
3. Borgna-Pignatti C., Rigolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., Romeo M.A., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Cnaan A. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
4. Yardumian A., Telfer P., Darbyshire P. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK, United Kingdom Thalassaemia Society 2008, 2nd edition.
5. Porter J., Cohen A., Kwiatkowski J. Transfusion and iron chelation. Disorders of Hemoglobin 2009, 689-744. Cambridge University Press, New York. M. Steinberg, B. Forget, D. Higgs, D. Weatheral (Eds.).
6. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br. J. Haematol. 2007, 138:407-421.
7. Electronic Medicines Compendium Desferal - Summary of Product Characteristics URL, Accessed 28 September 2006. http://emc.medicines.org.uk.
8. EMEA Ferriprox EPAR URL. http://www.emea.europa.eu/humandocs/Humans/EPAR/ferriprox/ferriprox.htm.
9. British Medical Association and Royal Pharmaceutical Society of Great Britain British National Formulary (BNF). No. 53, March 2007 2007, BMA and RPS, London, URL. http://www.bnf.org/bnf/.
10. EMEA Ferriprox: Annex I - Summary of Product Characteristics URL, Accessed 2 February 2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/ferriprox/ferriprox.htm.
11. Piga A., Galanello R., Forni G.L., Cappellini M.D., Origa R., Zappu A., Donato G., Bordone E., Lavagetto A., Zanaboni I., Sechaud R., Hewson N., Ford J.M., Pitz H.O., Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006, 91:873-880.
12. Origa R., Bina P., Agus A., Crobu G., Defraia E., Dessì C., Leoni G., Muroni P.P., Galanello R. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematological 2005, 90:1309-1314.
13. Tanner M.A., Galanello R., Dessi C., Smith G.C., Westwood M.A., Agus A., Roughton M., Assomull R., Nair S.V., Walker J.M., Pennell D.J. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007, 115:1876-1884.
14. Roberts D.J., Rees D., Howard J., Hyde C., Alderson P., Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst. Rev. 2005.
15. Addis A., Loebstein R., Koren G., Einarson T.R. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur. J. Clin. Pharmacol. 1999, 55:1-6.
16. Franchini M., Veneri D. Iron overload and hematologic malignancies. Hematol. J. 2004, 5:381-383.
17. Vanorden H.E., Hagemann T.M. Deferasirox - an oral agent for chronic iron overload. Ann. Pharmacother. 2006, 40:1110-1117.
18. Abetz L., Baladi J.F., Jones P., Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual. Life Outcomes 2006, 4:73.
19. McLeod C., Fleeman N., Kirkham J., Bagust A., Boland A., Chu P., Dickson R., Dundar Y., Greenhalgh J., Modell B., Olujohungbe A., Telfer P., Walley T. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol. Assess. 2009, 13:1-121.
20. Malaysian Health Technology Assessment Unit Management of Thalassemia Kuala Lumpur. Malaysian Health Technology Assessment Unit MHTAU 2003.
21. Caro J.J., Huybrechts K.F., Gree T.C. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC Blood Dis. 2002, 2:4.
22. Kjaergaard L., Villumsen J., Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Intern. Med. 2001, 135:982-989.
23. Moher D., Pham B., Jones A., Cook D.J., Jadad A.R., Moher M., Tugwell P., Klassen T.P. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. Lancet 1998, 352:609-613.
24. Wood L., Egger M., Gluud L.L., Schulz K.F., Jüni P., Altman D.G., Gluud C., Martin R.M., Wood A.J., Sterne J.A. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Br. Med. J. 2008, 336:601-605.
25. Crowther M., Lim W., Crowther M.A. Systematic review and meta-analysis methodology. Blood 2010, 116:3140-3146.
26. Review Manager Review Manager (RevMan) [Computer program]. Version 5.0 2008, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
27. Handbook rev man 5.0 (2008), http://ims.cochrane.org/revman/documentation.
28. Atkins D., Eccles M., Flottorp S., Guyatt G.H., Henry D., Hill S., Henry D., Hill S., Liberati A., O'Connell D., Oxman A.D., Phillips B., Schünemann H., Edejer T.T., Vist G.E., Williams J.W. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv. Res. 2004, 4:38. GRADE Working Group.
29. Aydinok Y., Ulger Z., Nart D., Terzi A., Cetiner N., Ellis G., Zimmermann A., Manz C. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007, 92:1599-1606.
30. Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematology 2007, 12:577-585.
31. Maggio A., Capra M., Pepe A., Mancuso L., Cracolici E., Vitabile S., Rigano P., Cassarà F., Midiri M. A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients. Pediatr. Endocrinol. Rev. 2008, 6:193-203.
32. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., Aydinok Y., Kattamis A., Kilinc Y., Porter J., Capra M., Galanello R., Fattoum S., Drelichman G., Magnano C., Verissimo M., Athanassiou-Metaxa M., Giardina P., Kourakli-Symeonidis A., Janka-Schaub G., Coates T., Vermylen C., Olivieri N., Thuret I., Opitz H., Ressayre-Djaffer C., Marks P., Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily iron chelator; in patients with beta-thalassemia. Blood 2006, 107:3455-3462.
33. Gomber S., Saxena R., Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004, 41:21-27.
34. Cogliandro T., Derchi G., Mancuso L., Mayer M.C., Pannone B., Pepe A., Pili M., Bina P., Cianciulli P., De Sanctis V., Maggio A. Guideline recommendations for heart complications in thalassemia major. J. Cardiovasc. Med (Hagerstown) 2008, 9:515-525.
35. Borgna-Pignatti C., Cappellini M.D., De Stefano P., Del Vecchio G.C., Forni G.L., Gamberini M.R., Ghilardi R., Piga A., Romeo M.A., Zhao H., Cnaan A. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006, 107:3733-3737.
36. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., Romeo M.A., Magnano C., Caruso V., Argento C., Gerardi C., Campisi S., Violi P., Malizia R., Cianciulli P., Rizzo M., D'Ascola D.G., Quota A., Prossomariti L., Fidone C., Rigano P., Pepe A., D'Amico G., Morabito A., Gluud G. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br. J. Haematol. 2009, 145:245-254.
37. Maggio A., Vitrano A., Capra M., Cuccia L., Gagliardotto F., Filosa A., Magnano C., Rizzo M., Caruso V., Gerardi C., Argento C., Campisi S., Cantella F., Commendatore F., D'Ascola D.G., Fidone C., Ciancio A., Galati M.C., Giuffrida G., Cingari R., Giugno G., Lombardo T., Prossomariti L., Malizia R., Meo A., Roccamo G., Romeo M.A., Violi P., Cianciulli P., Rigano P. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial Under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol. Dis. 2009, 42:247-251.
38. Modell B., Khan M., Darlison M., Westwood M.A., Ingram D., Pennell D.J. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J. Cardiovasc. Magn. Reson. 2008, 10:42.
39. Link G., Konijn A.M., Breuer W., Cabantchik Z.I., Hershko C. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J. Lab. Clin. Med. 2001, 138:130-138.
40. Giardina P.J., Grady R.W. Chelation therapy in beta-thalassemia: an optimistic update. Semin. Hematol. 2001, 38:360-366.
41. Pennell D.J., Berdoukas V., Karagiorga M., Ladis V., Piga A., Aessopos A., Gotsis E.D., Tanner M.A., Smith G.C., Westwood M.A., Wonke B., Galanello R. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood 2006, 107:3738-3744.
42. Cohen A.R., Glimm E., Porter J.B. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008, 111:583-587.
43. Taher A., El-Beshlawy A., Elalfy M.S., Al Zir K., Daar S., Habr D., Kriemler-Krahn U., Hmissi A., Al Jefri A. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur. J. Haematol. 2009, 82:458-465.
44. Galanello R., Kattamis A., Piga A., Fischer R., Leoni G., Ladis V., Voi V., Lund U., Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematological 2006, 91:1241-1243.
45. Ha S.Y., Chik K.W., Ling S.C., Lee A.C., Luk C.W., Lam C.W., Ng I.O., Chan G.C. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 2006, 30:263-274.
46. Nisbet-Brown E., Olivieri N.F., Giardina P.J., Grady R.W., Neufeld E.J., Sèchaud R., Krebs-Brown A.J., Anderson J.R., Alberti D., Sizer K.C., Nathan D.G. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003, 361:1597-1602.
47. Maggio A., D'Amico G., Morabito A., Capra M., Ciaccio C., Cianciulli P., Di Gregorio F., Garozzo G., Malizia R., Magnano C., Mangiagli A., Quarta G., Rizzo M., D'Ascola D.G., Rizzo A., Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol. Dis. 2002, 28:196-208.
48. Mourad F.H., Hoffbrand A.V., Sheikh-Taha M., Koussa S., Khoriaty A.L., Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br. J. Haematol. 2003, 121:187-189.
49. Yarali N., Fisgin T., Duru F., Kara A., Ecin N., Fitoz S., Erden I. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion. J. Pediatric. Hematol. Oncol. 2006, 28:11-16.
50. El-Beshkawy A., Manz C., Naja M., Eltagui M., Tarabishi C., Youssry I., Sobh H., Hamdy M., Sharaf I., Mostafa A., Shaker O., Hoffbrand A.V., Taher A. Iron chelation in thalassemia: combined or monotherapy ? The Egyptian experience. Ann. Hematol. 2008, 87:545-550.